Erdosteine Market Size is valued at USD 147.21 Mn in 2022 and is predicted to reach USD 301.61 Mn by the year 2031 at a 8.45% CAGR during the forecast period for 2023-2031.
The changing environment, including increased air pollution and cigarette or tobacco smoking, has resulted in an increase in respiratory disorders and ailments. Prolonged exposure to chemicals in industrial units, as well as indoor pollution in rural areas, leads to the increased prevalence of lung diseases/disorders. The airflow obstruction can cause chronic coughing, wheezing, nausea, and vomiting. It can also reduce the quality of life for those who are suffering. Growing emphasis on illness prevention rather than treatment, as well as government prioritization of healthcare resources, has resulted in increased use of erdosteine by research institutes.
The rising prevalence of chronic diseases in adults, such as obesity, diabetes, and heart disease, has boosted the demand for therapeutic treatments, which should propel the pharmaceutical research industry and boost the erdosteine market share.
Competitive Landscape
Some of the Erdosteine Market players are:
- Alitair Pharmaceuticals
- Berchemia Healthcare
- Delta Finochem Pvt. Ltd.
- Edmond Pharmaceuticals
- Hanmi Pharmaceuticals Co. Ltd.
- Hikma Pharmaceuticals
- Recipharm AB
- Shandong Luoxin Pharmaceuticals
- Shanghai Pukang Pharmaceutical
- Zhejiang Pharmaceutical Co. Ltd.
Market Segmentation:
The Erdosteine Market is segmented on the basis of end-user and application. End-user segment includes pharmaceutical, research institutes, contract manufacturing organizations, and others. By application, the market is segmented into bronchitis, chronic obstructive pulmonary disease, nasopharyngitis, and others.
Based On End-User, The Pharmaceutical Segment Is Accounted As A Major Contributor In The Erdosteine Market
The pharmaceutical category is expected to hold a major share of the global Erdosteine Market in 2022. The rising pharmaceutical sectors of India and China have considerably contributed to the segment's market expansion. Collaborations, mergers, acquisitions, partnerships, and agreements between market players to develop novel pharmaceuticals and product innovation in the pharmaceutical sector will help boost the segment's growth. Furthermore, the massive and extensive distribution and retail network of drug stores aids pharmaceutical growth by broadening their reach and boosting medicine accessibility. Increased R&D will also fuel the segment's growth. Furthermore, fiscal investment is expected to expand, assisting the pharmaceutical sector in growth during the projection period.
The Chronic Obstructive Pulmonary Disease (COPD) Segment Witnessed Growth At A Rapid Rate
The chronic obstructive pulmonary disease segment is projected to grow at a rapid rate in the global Erdosteine Market. COPD is a long-term inflammatory lung disorder that reduces airflow. Wheezing, coughing up mucus (sputum), and difficulty breathing are among the symptoms. The ageing population will boost the prevalence of COPD. Furthermore, rising e-cigarette and tobacco consumption will contribute to the global rise in COPD prevalence. COPD is prevalent, causing 3 to 4 million deaths worldwide each year. It is life-threatening if not treated and can progress to other catastrophic health concerns. As a result, the rising incidence and majority of chronic obstructive pulmonary disease will drive the segment's expansion.
The North America Erdosteine Market Holds A Significant Revenue Share In The Region
The North America Erdosteine Market is expected to report the highest market share in terms of revenue shortly. The region's young individuals are particularly vulnerable to smoking and tobacco consumption. The increasing popularity of e-cigarettes adds to the region's already pervasive substance misuse problem. Given the problematic job life or life, the stressful contemporary lifestyle has also boosted tobacco intake and cigarette smoking. Furthermore, occupational exposure to harmful particulates and rising air pollution in the Asia Pacific lead to chronic lung conditions/diseases. The pharmaceutical industry's vast and ever-expanding drug supply matches the need for erdosteine. Large pharmaceutical businesses in the region stimulate research and development of novel pharmaceuticals, ultimately boosting the region's growth. Rising government healthcare spending will help the growth of the regional erdosteine market in the coming years.
Erdosteine Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 147.21 Mn |
|
Revenue Forecast In 2031 |
USD 301.61 Mn |
|
Growth Rate CAGR |
CAGR of 8.45% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn, and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By End-user and Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Alitair Pharmaceuticals, Berchemia Healthcare, Delta Finochem Pvt. Ltd., Edmond Pharmaceuticals, Hanmi Pharmaceuticals Co. Ltd., Hikma Pharmaceuticals, Recipharm AB, Shandong Luoxin Pharmaceuticals, Shanghai Pukang Pharmaceutical, Zhejiang Pharmaceutical Co. Ltd. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
